153 related articles for article (PubMed ID: 17994370)
1. Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits.
Idell S; Azghani A; Chen S; Koenig K; Mazar A; Kodandapani L; Bdeir K; Cines D; Kulikovskaya I; Allen T
Exp Lung Res; 2007; 33(8-9):419-40. PubMed ID: 17994370
[TBL] [Abstract][Full Text] [Related]
2. Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease.
Strange C; Baumann MH; Sahn SA; Idell S
Am J Respir Crit Care Med; 1995 Feb; 151(2 Pt 1):508-15. PubMed ID: 7842213
[TBL] [Abstract][Full Text] [Related]
3. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
5. Intrapleural instillation of urokinase in the treatment of loculated pleural effusions in children.
Stringel G; Hartman AR
J Pediatr Surg; 1994 Dec; 29(12):1539-40. PubMed ID: 7877021
[TBL] [Abstract][Full Text] [Related]
6. The tissue plasminogen activator finger domain confers fibrin-dependent enhancement of catalytic activity to single-chain urokinase-type plasminogen activator.
Lubin IM; Caban R; Runge MS
J Biol Chem; 1993 Mar; 268(8):5550-6. PubMed ID: 8449917
[TBL] [Abstract][Full Text] [Related]
7. Local release of fibrinolytic agents for adhesion prevention.
Hill-West JL; Dunn RC; Hubbell JA
J Surg Res; 1995 Dec; 59(6):759-63. PubMed ID: 8538178
[TBL] [Abstract][Full Text] [Related]
8. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
9. Intrapleural fibrinolytic therapy for complicated pleural effusions.
Monroe BS; Warner D
Crit Care Nurse; 1998 Dec; 18(6):73-80. PubMed ID: 9887724
[TBL] [Abstract][Full Text] [Related]
10. Purification and characterization of tissue-type plasminogen activator in maxillary mucosa with chronic inflammation.
Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
Thromb Haemost; 1985 Aug; 54(2):485-9. PubMed ID: 3936218
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of a thrombin-activable plasminogen activator.
Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor.
Higazi A; Cohen RL; Henkin J; Kniss D; Schwartz BS; Cines DB
J Biol Chem; 1995 Jul; 270(29):17375-80. PubMed ID: 7615542
[TBL] [Abstract][Full Text] [Related]
13. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes.
Higazi AA; Bdeir K; Hiss E; Arad S; Kuo A; Barghouti I; Cines DB
Blood; 1998 Sep; 92(6):2075-83. PubMed ID: 9731065
[TBL] [Abstract][Full Text] [Related]
14. [Behavior of postoperative adhesions after intraperitoneal administration of fibrinolytic drugs in a rat model].
Stapel A; Geissler N; Mlasowsky B; Jung D
Langenbecks Arch Chir; 1997; 382(1):33-6. PubMed ID: 9157230
[TBL] [Abstract][Full Text] [Related]
15. Effects of tetracycline hydrochloride on pleurae in dogs with induced pleural effusion.
Gallagher LA; Birchard SJ; Weisbrode SE
Am J Vet Res; 1990 Oct; 51(10):1682-7. PubMed ID: 2240791
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and pleural reaction of doxycycline after intrapleural administration].
Homma T; Yoneda S; Komuro Y; Yoshida S; Min KY; Takayama S
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1129-34. PubMed ID: 6870294
[TBL] [Abstract][Full Text] [Related]
17. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
Maksimenko AV
Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
[TBL] [Abstract][Full Text] [Related]
18. TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial.
Goldhaber SZ
Vasa Suppl; 1989; 27():292-4. PubMed ID: 2516368
[No Abstract] [Full Text] [Related]
19. Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.
Light RW; Wang NS; Despars JA; Gruer SE; Sassoon C; Vargas FS
Lung; 1996; 174(6):373-81. PubMed ID: 8887932
[TBL] [Abstract][Full Text] [Related]
20. Tissue-type plasminogen activator and adhesion prevention.
Dunn RC
Prog Clin Biol Res; 1993; 381():213-20. PubMed ID: 8316565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
